Please wait while the transcript is being prepared...
0:00
Hello, my name is Bert O'Neil.
I'm a medical oncologist,
Professor of Oncology
at the Indiana University,
Simon Cancer Center in Indianapolis.
I'm pleased today to talk to you
about the topic
of Novel Treatments for GI Malignancies.
0:17
These are the topics
I've chosen to discuss today.
Obviously, new treatments of any cancer
can be a very broad area,
so I've picked a few
that I think are of current relevance.
These mostly relate to colorectal cancer
although some of what I'll speak about
relates to other GI malignancies as well.
Note that I have specifically
not chosen to talk about
immunotherapies today and believe
this will be covered in other lectures.
So the topics we will discuss
are HER2 and colorectal cancer.
We'll speak about what strategies
are being developed
for dealing with BRAF mutant
colorectal cancer.
And lastly, a new area
of cancer biology
which is, can we target stem cells
to treat GI malignancies.
1:03
HER2 overexpression is uncommon
but is seen in colorectal cancer.
In the largest study of this to date,
strong membranous staining
for HER2 was seen in only 25 of 1900
or 1.3% of stage II-III tumors
and 29 of 1300 or 2.2% of stage IV tumors
in a collection
of randomized clinical trials.
Interestingly, HER2 overexpression
is strongly associated with KRAS
and BRAF status.
For example, in the stage IV tumors,
HER2 positivity was seen in
5% of KRAS/BRAF wild-type cases,
versus only 1% of KRAS/BRAF mutant tumors.
